Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Intangibles (2023 - 2025)

Tarsus Pharmaceuticals (TARS) has 2 years of Intangibles data on record, last reported at $8.3 million in Q4 2024.

  • For Q4 2024, Intangibles rose 115.31% year-over-year to $8.3 million; the TTM value through Dec 2024 reached $8.3 million, up 115.31%, while the annual FY2024 figure was $8.3 million, 115.31% up from the prior year.
  • Intangibles reached $8.3 million in Q4 2024 per TARS's latest filing, up from $3.7 million in the prior quarter.
  • Across five years, Intangibles topped out at $8.3 million in Q4 2024 and bottomed at $3.7 million in Q2 2024.